Table 2.
Objective response rate (ORR) to first exposure checkpoint inhibitors
N (%) | Anti-PD-1 (N=180) | Anti-PD-1 +Ipilimumab (N=58) | Ipilimumab (N=82) |
ORR, % | 26 | 43 | 15 |
CR | 22 (12) | 8 (14) | 4 (5) |
PR | 25 (14) | 17 (29) | 8 (10) |
SD | 31 (17) | 7 (12) | 14 (17) |
PD | 102 (57) | 26 (45) | 56 (68) |
OR (95% CI) | 1 | 2.14 (1.16 to 3.97) | 0.49 (0.24 to 0.97) |
P value | – | 0.0004 | 0.0016 |
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.